Signs and symptoms of moderate to severe atopic dermatitis were significantly reduced with baricitinib 4 mg on top of topical corticosteroids, compared with placebo in the phase 3, BREEZE-AD7 study.
Medscape Medical News
…read more
Miami OBGYN Society
A Membership Organization of South Florida Obstetrician-Gynecologists
